CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Ticagrelor With or Without Aspirin After Complex PCI When, where, and how to target vascular inflammation in the post-CANTOS era? Post-stenting fractional flow reserve vs coronary angiography for optimisation of percutaneous coronary intervention: TARGET-FFR trial Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?
|<<... 126 127 128 129 130 131 132 ...>>|

Expert OpinionVolume 74, Issue 2, July 2019

JOURNAL：J Am Coll Cardiol. Article Link

Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials JACC Scientific Expert Panel

B Ibanez, AH Aletras, AE Arai et al. Keywords: area at risk; clinical trial; edema; endpoint; infarct size; magnetic resonance imaging; myocardial infarction; STEMI

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top